{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Recurrent+Papillomatosis+%28RRP%29",
    "query": {
      "condition": "Respiratory Recurrent Papillomatosis (RRP)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Recurrent+Papillomatosis+%28RRP%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T11:06:07.660Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07317154",
      "title": "Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2026-09",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07317154"
    },
    {
      "nct_id": "NCT03707587",
      "title": "M7824 in People With Recurrent Respiratory Papillomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Respiratory Papillomatosis",
        "Laryngeal Papilloma, Recurrent",
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "M7824",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-12-19",
      "completion_date": "2022-07-06",
      "has_results": true,
      "last_update_posted_date": "2022-09-29",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707587"
    },
    {
      "nct_id": "NCT00829608",
      "title": "Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Human Papillomavirus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-01",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829608"
    },
    {
      "nct_id": "NCT06538480",
      "title": "Zopa Retreatment and Vector Shedding in Adults With RRP",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Papillomavirus Infection",
        "Papillomaviridae"
      ],
      "interventions": [
        {
          "name": "Zopapogene imadenovec (Zopa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-07-11",
      "completion_date": "2028-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06538480"
    },
    {
      "nct_id": "NCT05797246",
      "title": "Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Diseases",
        "Neoplasms",
        "Neoplasms by Histologic Type",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms, Squamous Cell",
        "Tumor Virus Infections",
        "Infections",
        "Virus Diseases",
        "DNA Virus Infections",
        "Pathologic Processes",
        "Disease Attributes",
        "Recurrence",
        "Papilloma",
        "Respiratory Tract Infections",
        "Papillomavirus Infections"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-08-02",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797246"
    },
    {
      "nct_id": "NCT02859454",
      "title": "Avelumab for People With Recurrent Respiratory Papillomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Juvenile Laryngeal Papilloma",
        "Laryngeal Papilloma, Recurrent",
        "Respiratory Papillomatosis",
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 13,
      "start_date": "2016-08-06",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859454"
    },
    {
      "nct_id": "NCT04645602",
      "title": "Merck IIT: RRP Pembro and Lenvatinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papilloma Virus",
        "Recurrent Respiratory Papillomatosis",
        "Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-07-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04645602"
    },
    {
      "nct_id": "NCT00733252",
      "title": "Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer",
        "Malignant Mesothelioma",
        "Metastatic Cancer",
        "Nonmalignant Neoplasm",
        "Precancerous Condition"
      ],
      "interventions": [
        {
          "name": "bronchoscopic and lung imaging studies",
          "type": "PROCEDURE"
        },
        {
          "name": "diagnostic bronchoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "histopathologic examination",
          "type": "PROCEDURE"
        },
        {
          "name": "optical coherence tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2015-10-02",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733252"
    },
    {
      "nct_id": "NCT02632344",
      "title": "Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2016-04",
      "completion_date": "2025-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 2,
      "location_summary": "Evanston, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632344"
    },
    {
      "nct_id": "NCT04724980",
      "title": "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Papillomavirus Infections",
        "Papillomaviridae"
      ],
      "interventions": [
        {
          "name": "PRGN-2012 - Phase I; Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "PRGN-2012 - Phase I; Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "PRGN-2012 - Phase II; Dose Level 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2021-03-16",
      "completion_date": "2026-06-05",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-09T11:06:07.660Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04724980"
    }
  ]
}